Navigation Links
Omeros to Webcast Presentation at Deutsche Bank 35th Annual Health Care Conference
Date:4/29/2010

SEATTLE, April 29 /PRNewswire-FirstCall/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros, will present at the Deutsche Bank 35th Annual Health Care Conference in Boston on May 4, 2010 at 2:50 p.m. EDT.  The presentation will be webcast.  The live or archived webcast can be accessed on the "Events" page of the Company's website at www.omeros.com.

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has five ongoing clinical development programs, including four from its PharmacoSurgery™ platform and one from its Addiction program, the most advanced of which is in Phase 3 clinical trials. Omeros may also have the near-term capability, through its GPCR program, to add an unprecedented number of wholly new drug targets to the market
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
2. Omeros Appoints David A. Mann to its Board of Directors
3. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
4. Omeros and BlueCrest Announce $20 Million Debt Facility
5. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
6. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
7. Omeros Appoints New Vice President of Clinical Development
8. Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmologic Surgery
9. Omeros Commences Initial Public Offering of Common Stock
10. Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights
11. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... -- CORD:USE Cord Blood Bank – www.corduse.com ... into an Equity and Exclusive Services Agreement with Tianhe Stem ... patented technologies for the isolation of human cord blood-derived ... performing Phase I/II clinical trials in China ... Tianhe,s Stem Cell Educator Therapy showing that the therapy ...
(Date:9/30/2014)... 30, 2014 BioHealth Innovation, Inc. ... biohealth innovations and increasing access to early-stage funding in ... venture capitalist, Tania Fernandez , Ph.D., has joined ... will be a member of the management team for ... to $50 million in seed and early-stage equity investments ...
(Date:9/30/2014)... Stamford, CT (PRWEB) September 30, 2014 ... private non-profit funder of Lyme disease research at universities, ... to researchers focused on the identification, treatment and cure ... noted it had received the most applications in its ... year. , “While we were pleased to receive ...
(Date:9/30/2014)... Jersey (PRWEB) September 30, 2014 ... has been chosen by the Parenteral Drug Association ... 18 and 19, 2014) on container closure integrity testing. ... closure integrity test methods and philosophies detailed in the ... Integrity Evaluation. The course will span container ...
Breaking Biology Technology:CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 4Seasoned Life Sciences Venture Capitalist Tania Fernandez Joins BHI to Help Manage New BioHealth Gap Fund 2Lyme Research Alliance Awards Nearly $600,000 in New Grants 2Lyme Research Alliance Awards Nearly $600,000 in New Grants 3Lyme Research Alliance Awards Nearly $600,000 in New Grants 4Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 2Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 3Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 4
... technologys sake. And yet a visiting space alien that is ... for believing thats what most of us are doing. We ... the technology and almost none of our energy into assessing ... From the way we allocate our energy and attention, it ...
... MADISON, Wis. — With the University of Wisconsin System ... of creating two separate statewide networks, Gov. Jim Doyle ... efforts. , ,"It's more sensible for taxpayers to have ... spokesperson Dan Leistikow. , ,Initial discussions last year about ...
... a new product, behave just like parents jumping in ... of the incubation wing is often replaced by a ... Dilbertish style revolution. Objects do fly, even though they ... Everyone shares the excitement and all fights are well ...
Cached Biology Technology:Why are you buying technology? 2Why are you buying technology? 3Governor tells UW to scrap network plans 2Naming that thing... again? 2Naming that thing... again? 3Naming that thing... again? 4
(Date:9/30/2014)... Institutes of Health (NIH) awarded Lawrence Livermore National ... electrode array system that will enable researchers to ... resolution and scale. , LLNL,s grant-funded project is ... BRAIN (Brain Research through Advancing Innovative Neurotechnologies) ... our understanding of the human mind and uncover ...
(Date:9/30/2014)... of environmental scientists and engineers, led by Clemson ... three-year, $5.25 million grant from the U.S. Department ... to make a direct positive impact on South ... disposal of radioactive contaminants. , "Understanding the scientific ... with environmental aspects of nuclear technologies is imperative ...
(Date:9/30/2014)... New England Journal of Medicine reports positive results ... crizotinib against the subset of lung cancer marked by ... of 50 patients with advanced non-small cell lung cancer ... was 72 percent, with 3 complete responses and 33 ... takes for the disease to resume its growth after ...
Breaking Biology News(10 mins):NIH taps lab to develop sophisticated electrode array system to monitor brain act 2NIH taps lab to develop sophisticated electrode array system to monitor brain act 3Researchers get $5.25 million to advance nuclear technologies in South Carolina 2NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer 2
... Calif. Researchers at Sandia National Laboratories will use ... high-throughput assays as part of a multiproject, $34 ... (ARPA-E) aimed at developing advanced biocatalyst technologies that ... transportation. The ARPA-E program is Reducing Emissions ...
... scientific team has discovered a gene associated with a ... variant may be an actual cause of this form ... children. "Because asthma is a complex disease, with ... recurrent asthma occurring between ages two and six," said ...
... OVERVIEW: Straight from Stockholm: Randy Schekman, Ph.D., ... New Orleans after receiving the 2013 Nobel Prize in ... 2,500 poster presentations about the latest research on cellular ... cell interactions and the proverbial much, much more. ...
Cached Biology News:Converting natural gas to liquid transportation fuels via biological organisms 2Converting natural gas to liquid transportation fuels via biological organisms 3Novel gene variant found in severe childhood asthma 2
... Sepharose 4B, 10 ... purification of calmodulin-binding ... of calmodulin-regulated proteins ... cells. Category: Chromatography ...
...
Negative Control, eluted and packaged aseptically in 20l of 10mM Tris-HCL, pH 8.0, 1 mM EDTA, 5 years at either 4°C or -20°C...
Request Info...
Biology Products: